Rosemary: digestion, memory, forms and precautions

Rosemary (Salvia rosmarinus, formerly Rosmarinus officinalis) is both a culinary herb and a plant sold in more concentrated medicinal forms. These uses are not interchangeable. For digestion, the European Medicines Agency (EMA) recognises a traditional medicinal use of rosemary leaf for symptomatic relief of dyspepsia and mild spasmodic gastrointestinal complaints. Human evidence for memory is much more limited.

The EMA monograph concerns rosemary-leaf medicines and relies on longstanding use, not on modern clinical proof of an effect above placebo. Dyspepsia can include difficult digestion or discomfort; this framework does not explain every abdominal pain or persistent digestive problem.

If symptoms last more than two weeks during use of a rosemary-leaf medicine, or worsen, the EMA advises consulting a doctor or pharmacist. Severe pain, persistent vomiting, blood in the stool or unexplained weight loss also warrant medical advice.

Frequently cited results do not justify calling a memory effect established. A narrative review included five rosemary studies among work on several plants; preparations, populations and methods were heterogeneous.

The important point is scope: one study of one preparation does not show that rosemary prevents cognitive decline, treats a neurological disease or durably improves memory in the general population. Preclinical findings can generate hypotheses but do not replace human trials.

An infusion, a medicinal leaf preparation, an extract and an essential oil do not produce the same exposure; a result obtained with one form does not automatically validate the others. Culinary use and a medicinal preparation also have different purposes and quality requirements.

Label details matter: plant part, extract, solvent, possible chemotype and amount do not describe the same product. The article on ginger and its forms illustrates the same rule: evidence must remain attached to the preparation studied.

The EMA advises against rosemary-leaf medicines during pregnancy and breastfeeding, before age 12, and in bile-duct obstruction, gallbladder inflammation, gallstones or liver disease. Hypersensitivity, including contact dermatitis, is also possible.

Food use is not equivalent to medicinal use. Do not turn a laboratory mechanism into practical advice: a plausible mechanism does not say which form to use or who can use it safely.

EMA, 2026 — Rosmarini folium EMA/HMPC, 2024 — EU herbal monograph Sayorwan et al., 2018 — PMID 29389474 Perry et al., 2017 — DOI 10.1016/j.eujim.2017.08.013 NCCIH, 2024 — Herb-drug interactions EMA/HMPC, 2026 — Public assessment summary